Mydecine Innovations Group Inc.
MYCO
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -68.73% | -68.77% | -58.31% | -34.11% | -31.11% |
| Depreciation & Amortization | -100.00% | -97.22% | -94.01% | -92.76% | -92.47% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.88% | -57.21% | -59.50% | -42.62% | -38.61% |
| Operating Income | 46.88% | 57.21% | 59.50% | 42.62% | 38.59% |
| Income Before Tax | 22.54% | 33.66% | 34.89% | -39.97% | 22.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.54% | 33.66% | 34.89% | -39.97% | 22.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 1,835.36% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.13% | 3.53% | 5.80% | -130.22% | 49.91% |
| EBIT | 46.88% | 57.21% | 59.50% | 42.62% | 38.59% |
| EBITDA | 46.87% | 57.12% | 59.35% | 42.20% | 38.24% |
| EPS Basic | 48.44% | 66.70% | 70.04% | 52.19% | 87.83% |
| Normalized Basic EPS | 74.65% | 79.88% | 79.89% | 80.38% | 81.62% |
| EPS Diluted | 48.44% | 66.70% | 70.04% | 52.19% | 87.83% |
| Normalized Diluted EPS | 74.65% | 79.88% | 79.89% | 80.38% | 81.62% |
| Average Basic Shares Outstanding | 165.88% | 193.32% | 228.42% | 258.58% | 222.32% |
| Average Diluted Shares Outstanding | 165.88% | 193.32% | 228.42% | 258.58% | 222.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
